Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-Youth: OLZ/SAM vs Olanzapine in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064Phase 3Recruiting
- Sponsor
- Alkermes
- Start
- Jun 2022
- Primary completion
- Sep 2026
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 5
01
Overview
A Phase 3 trial of samidorphan in schizophrenia, bipolar I disorder, sponsored by Alkermes. Started Jun 2022; status: recruiting.
02
Drugs
samidorphan
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT05303064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303064.